ELSEVIER

Clinica Chimica Acta 271 (1998) 221–222

Author index

Volume 271 (1998)

Adami, S., see Lippi, G. **271**, 79
Adlouni, A., Ghalim, N., Saïle, R., Hda, N., Parra, H.-J., Benslimane, A., Beneficial effect on serum apo AI, apo B and Lp AI levels of Ramadan fasting **271**, 179
Altamentova, S.M., Shaklai, N., Arav, R., Miller, Y.I., A fluorescence method for estimation of toxemia: binding capacity of lipoproteins and albumin in plasma **271**, 133
Anuradha, C.V., Balakrishnan, S.D., Increased lipoprotein susceptibility to oxidation following long distance running in trained subjects **271**, 97
Arav, R., see Altamentova, S.M. **271**, 133

Balakrishnan, S.D., see Anuradha, C.V. **271**, 97
Baumann, P., see Eap, C.B. **271**, 105
Bembi, B., see Gornati, R. **271**, 151
Benslimane, A., see Adlouni, A. **271**, 179
Boscolo, R., see Gornati, R. **271**, 151
Botella, M.-S., see Vera-Sempere, F. **271**, 119
Braga, V., see Lippi, G. **271**, 79
Brindle, E., see Holman, D.J. **271**, 25
Berra, B., see Gornati, R. **271**, 151
Buchwalder, P.A., see Eap, C.B. **271**, 105
Buclin, T., see Eap, C.B. **271**, 105
Burgos, J., see Vera-Sempere, F. **271**, 119

Campbell, K.L., see Holman, D.J. **271**, 25
Chichibu, K., see Kiyohara, T. **271**, 109
Chrostek, L., Szmitkowski, M., Serum activities of classes I and II alcohol dehydrogenases in toxic liver damage **271**, 163

Dwek, M.V., Lacey, H.A., Leathem, A.J.C., Breast cancer progression is associated with a reduction in the diversity of sialylated and neutral oligosaccharides **271**, 191

Eap, C.B., Buclin, T., Buchwalder, P.A., Gutmann, N., Baumann, P., Multiple and simultaneous phenotyping tests: beware of ascorbic acid when determining the mephenytoin (S)/(R) ratio **271**, 105
Eveland, B.J., see Way, B.A. **271**, 1

Fuentes-Arderiu, X., see Valero-Politi, J. **271**, 57
Fukuda, Y., see Ikemotoa, M. **271**, 11

Gacko, M., Głowiński, S., Activities of proteases in parietal thrombus of aortic aneurysm **271**, 171
Ghalim, N., see Adlouni, A. **271**, 179
Gornati, R., Bembi, B., Tong, X., Boscolo, R., Berra, B., Total glycolipid and glucosylceramide content in serum and urine of patients with Gaucher's disease type 3 before and after enzyme replacement therapy **271**, 151
Góth, L., Genetic heterogeneity of the 5′ uncoding region of the catalase gene in Hungarian acatalasemic and hypocatalasemic subjects **271**, 73
Głowiński, S., see Gacko, M. **271**, 171
Guidi, G., see Lippi, G. **271**, 79
Gutmann, N., see Eap, C.B. **271**, 105

Hda, N., see Adlouni, A. **271**, 179
Holman, D.J., Rasheed, F.N., Stroud, C.M., Brindle, E., O'Connor, K.A., Campbell, K.L., A commercial pregnancy test modified for field studies of fetal loss **271**, 25

Ikemotoa, M., Tsunekawa, S., Tanaka, K., Tanaka,

0009-8981/98/$19.00 Elsevier Science B.V. All rights reserved
PII S0009-8981(98)00027-8

A., Yamaoka, Y., Ozawa, K., Fukuda, Y., Moriyasu, F., Totani, M., Kasai, Y., Mori, T., Ueda, K., Liver-type arginase in serum during and after liver transplantation: a novel index in monitoring conditions of the liver graft and its clinical significance **271**, 11
Inazu, A., see Kiyohara, T. **271**, 109
Iqbal, S.J., Persistently raised serum acid phosphatase activity in a patient with hypophosphatasia: electrophoretic and molecular weight characterisation as type 5 **271**, 213

Jakobs, C., see Jansen, G.A. **271**, 203
Jansen, G.A., Mihalik, S.J., Watkins, P.A., Jakobs, C., Moser, H.W., Wanders, R.J.A., Characterization of phytanoyl-Coenzyme A hydroxylase in human liver and activity measurements in patients with peroxisomal disorders **271**, 203
Jin Lee, M., Nishio, H., Nagai, T., Okamoto, N., Yuki, T., Sumino, K., Molecular genetic analysis of the Prader–Willi syndrome by using fluorescent multiplex PCR of the dinucleotide repeats on chromosome 15q11–q13 **271**, 89

Kasai, Y., see Ikemotoa, M. **271**, 11
Kiriyama, R., see Kiyohara, T. **271**, 109
Kiyohara, T., Kiriyama, R., Zamma, S., Inazu, A., Koizumi, J., Mabuchi, H., Chichibu, K., Enzyme immunoassay for cholesteryl ester transfer protein in human serum **271**, 109
Knoch, K.-P., see Koslowski, R. **271**, 45
Koenig, J.W., see Way, B.A. **271**, 1
Koizumi, J., see Kiyohara, T. **271**, 109
Koslowski, R., Knoch, K.-P., Wenzel, K.-W., Proteinases and proteinase inhibitors during the development of pulmonary fibrosis in rat **271**, 45

Lacey, H.A., see Dwek, M.V. **271**, 191
Leathem, A.J.C., see Dwek, M.V. **271**, 191
Lippi, G., Braga, V., Adami, S., Guidi, G., Modification of serum apolipoprotein AI, apolipoprotein B and lipoprotein(a) levels after bisphosphonates-induced acute phase response **271**, 79

Mabuchi, H., see Kiyohara, T. **271**, 109
Mihalik, S.J., see Jansen, G.A. **271**, 203
Miller, Y.I., see Altamentova, S.M. **271**, 133
Morera, C., see Vera-Sempere, F. **271**, 119
Mori, T., see Ikemotoa, M. **271**, 11
Moriyasu, F., see Ikemotoa, M. **271**, 11
Moser, H.W., see Jansen, G.A. **271**, 203

Nagai, T., see Jin Lee, M. **271**, 89
Nishio, H., see Jin Lee, M. **271**, 89

O'Connor, K.A., see Holman, D.J. **271**, 25
Okamoto, N., see Jin Lee, M. **271**, 89
Ozawa, K., see Ikemotoa, M. **271**, 11

Parra, H.-J., see Adlouni, A. **271**, 179

Rasheed, F.N., see Holman, D.J. **271**, 25

Saïle, R., see Adlouni, A. **271**, 179
Scott, M.G., see Way, B.A. **271**, 1
Shaklai, N., see Altamentova, S.M. **271**, 133
Stroud, C.M., see Holman, D.J. **271**, 25
Sumino, K., see Jin Lee, M. **271**, 89
Szmitkowski, M., see Chrostek, L. **271**, 163

Tanaka, A., see Ikemotoa, M. **271**, 11
Tanaka, K., see Ikemotoa, M. **271**, 11
Tong, X., see Gornati, R. **271**, 151
Totani, M., see Ikemotoa, M. **271**, 11
Tsunekawa, S., see Ikemotoa, M. **271**, 11

Ueda, K., see Ikemotoa, M. **271**, 11

Valero-Politi, J., Fuentes-Arderiu, X., Annual rhythmic variations of follitropin, lutropin, testosterone and sex-hormone-binding globulin in men **271**, 57
Vera-Sempere, F., Burgos, J., Botella, M.-S., Morera, C., Comparative analysis of Epstein–Barr virus (EBV) detection by nested-PCR and non-isotopic in situ hybridization in nasopharyngeal carcinoma (NPC) **271**, 119

Walton, K.G., see Way, B.A. **271**, 1
Wanders, R.J.A., see Jansen, G.A. **271**, 203
Watkins, P.A., see Jansen, G.A. **271**, 203
Way, B.A., Walton, K.G., Koenig, J.W., Eveland, B.J., Scott, M.G., Comparison between the CEDIA and EMIT II immunoassays for the determination of benzodiazepines **271**, 1
Wenzel, K.-W., see Koslowski, R. **271**, 45

Yamaoka, Y., see Ikemotoa, M. **271**, 11
Yuki, T., see Jin Lee, M. **271**, 89

Zamma, S., see Kiyohara, T. **271**, 109

ELSEVIER

Clinica Chimica Acta 271 (1998) 223–225

Subject index

Volume 271 (1998)

Acatalasemia; Hypocatalasemia; SSCP; Sequence analyses **271**, 73

Acid phosphatase; Hypophosphatasia; Alkaline phosphatase; Tartrate resistant acid phosphatase (TRAP) **271**, 213

Activities of proteases; Aortic aneurysm; Parietal thrombus **271**, 171

Acute phase; Lipoprotein(a); Apolipoprotein; Bisphosphonates; Paget's disease **271**, 79

Albumin; Lipoprotein susceptibility to oxidation; Ceruloplasmin; Long distance running **271**, 95

Albumin; Lipoprotein; Fluorescent probes; Binding capacity; Toxins; Drugs **271**, 133

Alcohol dehydrogenase isoenzymes; Toxic liver damage **271**, 163

Alkaline phosphatase; Hypophosphatasia; Acid phosphatase; Tartrate resistant acid phosphatase (TRAP) **271**, 213

Aortic aneurysm; Parietal thrombus; Activities of proteases **271**, 171

Apolipoproteins; Lipoprotein particles; Ramadan fasting; Cardiovascular risk **271**, 179

Apolipoprotein; Lipoprotein(a); Acute phase; Bisphosphonates; Paget's disease **271**, 79

Autoantibody; Enzyme leakage; Urea cycle; Short half-life; Hepatic marker **271**, 11

Bangladesh; Human chorionic gonadotropin; Fetal mortality; Pregnancy diagnosis; Field methods; Urinary assays **271**, 25

Binding capacity; Lipoprotein; Albumin; Fluorescent probes; Toxins; Drugs **271**, 133

Bisphosphonates; Lipoprotein(a); Apolipoprotein; Acute phase; Paget's disease **271**, 79

Bleomycin; Elastase; Elastase inhibitors; Cathepsins; Lung fibrosis **271**, 45

Breast cancer; Progression; Prognosis; Oligosaccharide; Glycosylation **271**, 191

$(CA)_n$ dinucleotide repeat polymorphisms; Prader–Willi syndrome; Chromosome 15; Deletion; Maternal uniparental disomy **271**, 87

Cardiovascular risk; Apolipoproteins; Lipoprotein particles; Ramadan fasting **271**, 179

Cathepsins; Bleomycin; Elastase; Elastase inhibitors; Lung fibrosis **271**, 45

Ceruloplasmin; Lipoprotein susceptibility to oxidation; Albumin; Long distance running **271**, 95

Cholesteryl ester transfer protein (CETP); Sandwich immunoassay; Genetic deficiency **271**, 109

Chromosome 15; Prader–Willi syndrome; $(CA)_n$ dinucleotide repeat polymorphisms; Deletion; Maternal uniparental disomy **271**, 87

0009-8981/98/$19.00 Elsevier Science B.V. All rights reserved
PII S0009-8981(98)00028-X

Circannual; Rhythmic variations; Testosterone; Saliva; Follitropin; Lutropin **271**, 57

Cloned-enzyme donor immunoassay; Drugs-of-abuse **271**, 1

Deletion; Prader–Willi syndrome; Chromosome 15; $(CA)_n$ dinucleotide repeat polymorphisms; Maternal uniparental disomy **271**, 87

Drugs-of-abuse; Cloned-enzyme donor immunoassay **271**, 1

Drugs; Lipoprotein; Albumin; Fluorescent probes; Binding capacity; Toxins **271**, 133

Elastase inhibitors; Bleomycin; Elastase; Cathepsins; Lung fibrosis **271**, 45

Elastase; Bleomycin; Elastase inhibitors; Cathepsins; Lung fibrosis **271**, 45

Enzyme leakage; Urea cycle; Autoantibody; Short half-life; Hepatic marker **271**, 11

Enzyme replacement therapy; Gaucher type 3; Serum analysis; Urine analysis **271**, 151

Epstein–Barr virus; In situ hybridization; Nasopharyngeal carcinoma; Nested-polymerase chain reaction **271**, 119

Fatty acid oxidation; Peroxisomes; Phytanic acid; Refsum disease; Rhizomelic chondrodysplasia punctata; Zellweger syndrome **271**, 203

Fetal mortality; Human chorionic gonadotropin; Pregnancy diagnosis; Field methods; Urinary assays; Bangladesh **271**, 25

Field methods; Human chorionic gonadotropin; Fetal mortality; Pregnancy diagnosis; Urinary assays; Bangladesh **271**, 25

Fluorescent probes; Lipoprotein; Albumin; Binding capacity; Toxins; Drugs **271**, 133

Follitropin; Rhythmic variations; Circannual; Testosterone; Saliva; Lutropin **271**, 57

Gaucher type 3; Enzyme replacement therapy; Serum analysis; Urine analysis **271**, 151

Genetic deficiency; Cholesteryl ester transfer protein (CETP); Sandwich immunoassay **271**, 109

Glycosylation; Breast cancer; Progression; Prognosis; Oligosaccharide **271**, 191

Hepatic marker; Enzyme leakage; Urea cycle; Autoantibody; Short half-life **271**, 11

Human chorionic gonadotropin; Fetal mortality; Pregnancy diagnosis; Field methods; Urinary assays; Bangladesh **271**, 25

Hypocatalasemia; Acatalasemia; SSCP; Sequence analyses **271**, 73

Hypophosphatasia; Alkaline phosphatase; Acid phosphatase; Tartrate resistant acid phosphatase (TRAP) **271**, 213

In situ hybridization; Epstein–Barr virus; Nasopharyngeal carcinoma; Nested-polymerase chain reaction **271**, 119

Lipoprotein particles; Apolipoproteins; Ramadan fasting; Cardiovascular risk **271**, 179

Lipoprotein susceptibility to oxidation; Ceruloplasmin; Albumin; Long distance running **271**, 95

Lipoprotein(a); Apolipoprotein; Acute phase; Bisphosphonates; Paget's disease **271**, 79

Lipoprotein; Albumin; Fluorescent probes; Binding capacity; Toxins; Drugs **271**, 133

Long distance running; Lipoprotein susceptibility to oxidation; Ceruloplasmin; Albumin **271**, 95

Lung fibrosis; Bleomycin; Elastase; Elastase inhibitors; Cathepsins **271**, 45

Lutropin; Rhythmic variations; Circannual; Testosterone; Saliva; Follitropin **271**, 57

Maternal uniparental disomy; Prader–Willi syndrome; Chromosome 15; $(CA)_n$ dinucleotide repeat polymorphisms; Deletion **271**, 87

Nasopharyngeal carcinoma; Epstein–Barr virus; In situ hybridization; Nested-polymerase chain reaction **271**, 119

Nested-polymerase chain reaction; Epstein–Barr virus; In situ hybridization; Nasopharyngeal carcinoma **271**, 119

Oligosaccharide; Breast cancer; Progression; Prognosis; Glycosylation **271**, 191

Paget's disease; Lipoprotein(a); Apolipoprotein; Acute phase; Bisphosphonates **271**, 79

Parietal thrombus; Aortic aneurysm; Activities of proteases **271**, 171

Peroxisomes; Phytanic acid; Fatty acid oxidation; Refsum disease; Rhizomelic chondrodysplasia punctata; Zellweger syndrome **271**, 203

Phytanic acid; Peroxisomes; Fatty acid oxidation; Refsum disease; Rhizomelic chondrodysplasia punctata; Zellweger syndrome **271**, 203

Prader–Willi syndrome; Chromosome 15; $(CA)_n$ dinucleotide repeat polymorphisms; Deletion; Maternal uniparental disomy **271**, 87

Pregnancy diagnosis; Human chorionic gonadotropin; Fetal mortality; Field methods; Urinary assays; Bangladesh **271**, 25

Prognosis; Breast cancer; Progression; Oligosaccharide; Glycosylation **271**, 191

Progression; Breast cancer; Prognosis; Oligosaccharide; Glycosylation **271**, 191

Ramadan fasting; Apolipoproteins; Lipoprotein particles; Cardiovascular risk **271**, 179

Refsum disease; Peroxisomes; Phytanic acid; Fatty acid oxidation; Rhizomelic chondrodysplasia punctata; Zellweger syndrome **271**, 203

Rhizomelic chondrodysplasia punctata; Peroxisomes; Phytanic acid; Fatty acid oxidation; Refsum disease; Zellweger syndrome **271**, 203

Rhythmic variations; Circannual; Testosterone; Saliva; Follitropin; Lutropin **271**, 57

SSCP; Acatalasemia; Hypocatalasemia; Sequence analyses **271**, 73

Saliva; Rhythmic variations; Circannual; Testosterone; Follitropin; Lutropin **271**, 57

Sandwich immunoassay; Cholesteryl ester transfer protein (CETP); Genetic deficiency **271**, 109

Sequence analyses; Acatalasemia; Hypocatalasemia; SSCP **271**, 73

Serum analysis; Gaucher type 3; Enzyme replacement therapy; Urine analysis **271**, 151

Short half-life; Enzyme leakage; Urea cycle; Autoantibody; Hepatic marker **271**, 11

Tartrate resistant acid phosphatase (TRAP); Hypophosphatasia; Alkaline phosphatase; Acid phosphatase **271**, 213

Testosterone; Rhythmic variations; Circannual; Saliva; Follitropin; Lutropin **271**, 57

Toxic liver damage; Alcohol dehydrogenase isoenzymes **271**, 163

Toxins; Lipoprotein; Albumin; Fluorescent probes; Binding capacity; Drugs **271**, 133

Urea cycle; Enzyme leakage; Autoantibody; Short half-life; Hepatic marker **271**, 11

Urinary assays; Human chorionic gonadotropin; Fetal mortality; Pregnancy diagnosis; Field methods; Bangladesh **271**, 25

Urine analysis; Gaucher type 3; Enzyme replacement therapy; Serum analysis **271**, 151

Zellweger syndrome; Peroxisomes; Phytanic acid; Fatty acid oxidation; Refsum disease; Rhizomelic chondrodysplasia punctata **271**, 203